Cargando…

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers

BRAF mutant metastatic colorectal cancer has long been considered a tumor with a poor prognosis and a poor response to chemotherapy. Despite the efficacy of targeted therapy with multi-targeted blockade of the mitogen-activated protein kinase (MAPK) signaling pathway has brought a glimmer of hope to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhong, Jie, Sun, Zijian, Li, Sheng, Yang, Liu, Cao, Yuepeng, Bao, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10258190/ https://www.ncbi.nlm.nih.gov/pubmed/37302081 http://dx.doi.org/10.1007/s12672-023-00718-y

Ejemplares similares

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
por: Ascierto, Paolo A., et al.
Publicado: (2019)

Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAF(V600E)-Mutant Colorectal Cancer
por: Napolitano, Stefania, et al.
Publicado: (2023)

Real‐world treatment and outcomes of patients with metastatic BRAF mutant colorectal cancer
por: Xu, Ting, et al.
Publicado: (2023)

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
por: Bollag, Gideon, et al.
Publicado: (2010)

Targeting mutant BRAF in colorectal cancer
por: Carroll, David, et al.
Publicado: (2013)

Molecular mechanisms underlying the resistance of BRAF V600E-mutant metastatic colorectal cancer to EGFR/BRAF inhibitors
por: Xu, Ting, et al.
Publicado: (2022)

The Evolutionary Landscape of Treatment for BRAF(V600E) Mutant Metastatic Colorectal Cancer
por: Mauri, Gianluca, et al.
Publicado: (2021)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
por: Pan, Jing-hua, et al.
Publicado: (2018)

Dual BRAF/MEK blockade restores CNS responses in BRAF-mutant Erdheim–Chester disease patients following BRAF inhibitor monotherapy
por: Mazor, Roei D, et al.
Publicado: (2020)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive
por: Ghate, Sameer, et al.
Publicado: (2019)

Emerging treatment options for BRAF-mutant colorectal cancer
por: Ursem, Carling, et al.
Publicado: (2018)

Combination drug development in BRAF mutant colorectal cancer
por: Lam, Michael, et al.
Publicado: (2018)

Molecular targeted therapy of BRAF-mutant colorectal cancer
por: Ducreux, Michel, et al.
Publicado: (2019)

The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis
por: Gelsomino, Fabio, et al.
Publicado: (2020)

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
por: Capaldo, Brian J., et al.
Publicado: (2015)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades
por: Kang, Hongen, et al.
Publicado: (2023)

MCT4 blockade increases the efficacy of immune checkpoint blockade
por: Babl, Nathalie, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
por: Perdikis-Prati, Sarah, et al.
Publicado: (2023)

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas
por: Mehdi, A., et al.
Publicado: (2023)

Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
por: Gubin, Matthew M., et al.
Publicado: (2014)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Samlowski, Wolfram, et al.
Publicado: (2021)

Chromosomal Instability in BRAF Mutant, Microsatellite Stable Colorectal Cancers
por: Bond, Catherine E., et al.
Publicado: (2012)

BRAF-MEK inhibitors as steroid-sparing bridge prior to checkpoint blockade therapy in symptomatic intracranial melanoma
por: Khaddour, Karam, et al.
Publicado: (2021)

Exploring the best treatment options for BRAF-mutant metastatic colon cancer
por: Taieb, Julien, et al.
Publicado: (2019)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
por: Yang, Richard K., et al.
Publicado: (2020)

Is there a role for immune checkpoint blockade in metastatic uveal melanoma?
por: Schilling, Bastian, et al.
Publicado: (2015)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report
por: Peker, Yasar Subutay, et al.
Publicado: (2018)

Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer
por: Carter, Rebecca, et al.
Publicado: (2019)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_digu3uh8cd75lkvl0jvrcmg0dt